Mometasone Nasal Spray
Brand names: Nasonex, Clarinaze (with loratadine)
Mometasone furoate nasal spray is an intranasal corticosteroid used for allergic rhinitis and as a component of nasal polyp management, delivering anti-inflammatory steroid directly to the nasal mucosa with minimal systemic exposure.
Adult dose
Paediatric dose
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance, mometasone furoate, or to any of the excipients
- Should not be used in the presence of untreated localised infection involving the nasal mucosa, such as herpes simplex
- Patients who have experienced recent nasal surgery or trauma should not use a nasal corticosteroid until healing has occurred, because of the inhibitory effect of corticosteroids on wound healing
Side effects
- Very common: epistaxis (recorded for twice daily dosing for nasal polyposis); throat irritation (twice daily polyposis dosing)
- Common: epistaxis — generally self-limiting and mild, 5% in allergic rhinitis studies versus up to 15% for the active control nasal corticosteroids
- Common: pharyngitis; headache
- Common: nasal burning, nasal irritation
- Not known: hypersensitivity including anaphylactic reactions, angioedema, bronchospasm and dyspnoea
- Not known: glaucoma, increased intraocular pressure, cataracts, vision blurred
- Not known: nasal ulceration, nasal septum perforation
- Not known: disturbances of taste and smell
- Upper respiratory tract infection (uncommon with twice daily polyposis dosing)
- Paediatric population: adverse events in clinical studies — epistaxis (6%), headache (3%), nasal irritation (2%) and sneezing (2%) — were comparable to placebo
Monitoring
- SPC 4.4: 'patients using NASONEX Nasal Spray over several months or longer should be examined periodically for possible changes in the nasal mucosa. If localised fungal infection of the nose or pharynx develops, discontinuance of NASONEX Nasal Spray therapy or appropriate treatment may be required. Persistence of nasopharyngeal irritation may be an indication for discontinuing' treatment.
- SPC 4.4: 'Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods... Potential systemic effects may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).'
- SPC 4.4: 'Following the use of intranasal corticosteroids, instances of increased intraocular pressure have been reported.' If a patient reports blurred vision or other visual disturbance, consider referral to an ophthalmologist for possible cataract, glaucoma or central serous chorioretinopathy.
- Use with caution, if at all, in active or quiescent tuberculous infection of the respiratory tract, or untreated fungal, bacterial or systemic viral infections. Warn potentially immunosuppressed patients about exposure to chickenpox and measles.
- Not recommended in nasal septum perforation.
- Contains benzalkonium chloride, which 'may cause irritation or swelling inside the nose, especially if used for a long time'.
- Nasal polyposis: re-evaluate at 5 to 6 weeks if symptoms are inadequately controlled, and again if there is no improvement after 5 to 6 weeks of twice daily dosing.
- This list may be incomplete — check the full SPC.
Clinical monograph
How it works
Mometasone is a potent topical glucocorticoid that acts on nasal mucosal cells to suppress inflammatory mediator release and reduce mucosal oedema, easing congestion, rhinorrhoea and sneezing.
Prescribing in practice
- Correct technique — aiming the spray away from the nasal septum — reduces the risk of epistaxis, nasal irritation and, rarely, septal perforation with prolonged use.
- Full benefit develops over days of regular use, so it should be taken continuously rather than as required during the relevant season.
- Long-term use, particularly alongside inhaled or other corticosteroids, warrants awareness of cumulative steroid load and, in children, periodic height monitoring.
Monitoring
Periodically check inhalation/intranasal technique and inspect for nasal irritation or bleeding, and monitor growth in children on prolonged treatment.
Counselling the patient
- Use it every day as prescribed; it may take several days to work fully.
- Aim the nozzle slightly outward, away from the middle wall of the nose, to reduce nosebleeds.
- Tell your clinician about persistent nosebleeds, crusting or a whistling sound when breathing.
Evidence & guidelines
Intranasal mometasone is a guideline-recommended first-line treatment for moderate-to-severe allergic rhinitis and is established in nasal polyp care, supported by NICE and the SPC.
Reference: NICE NG174; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Steroid Dose Equivalence · Medications
- Lund-Mackay CT Score for Chronic Rhinosinusitis · Sinonasal
- SNOT-22 (Sinonasal Outcome Test) · Chronic Rhinosinusitis
- Epistaxis Severity Score (ESS) for HHT · Epistaxis
- Lille Model for Alcoholic Hepatitis · Hepatology
- FAST Exam Protocol — Focused Assessment with Sonography in Trauma · Trauma
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020